MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'deals'. Sat, 03 Sep 2011 02:11:44 +0100 http://www.medworm.com/index.php?rid=4862511&cid=t_148568_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2F80qXXWymvBI%2F By Sallie JamesOn Monday, a group of 41 Senate Democrats, led by Sen. Debbie Stabenow (MI) sent a letter to President Obama, praising his administration’s recent decision to abandon its erstwhile promotion of the three pending trade deals as “job creators” and instead warn Congress it won’t submit the pacts for a vote unless they can be assured that a stimulus-enhanced version of trade adjustment assistance will be renewed. The letter contains much about the benefits of the program, with little mention of its costs to taxpayers and even less concern shown for the innocent consumers whose pockets have been picked for decades to maintain the jobs lost when trade is allowed to flow more freely. That’s pretty standard fare for protectionists, who rely on the hid... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=4862511 Wed, 25 May 2011 15:41:30 +0100 4862511 http://www.medworm.com/index.php?rid=4803232&cid=t_148568_109_f&fid=34750&url=http%3A%2F%2Fpsychcentral.com%2Fblog%2Farchives%2F2011%2F05%2F10%2Fbest-of-our-blogs-may-10-2011%2F A friend once asked me how to handle her disobedient son. She was going through a divorce and her son was taking out his pain, confusion and anger about his parent’s relationship on her. She wanted to distance herself from him because he was being so hurtful. But I told her to reconsider. My mom and I have an imperfectly perfect relationship. We’re close. But we rarely see eye to eye on anything. We’re as different as we are alike. I like to find good deals. She loves brand names. She chose a traditional 9 to 5 job. I went the opposite way and designed my own career. At the same time, we’re both sensitive and emotional, which is the perfect recipe for personal and sometimes heated debates. But I have to say one thing. I grew up as a child of divorce too. And I told ... World of Psychology blogs http://www.medworm.com/rss/comments.php?id=4803232 Tue, 10 May 2011 11:50:07 +0100 4803232 http://www.medworm.com/index.php?rid=3827042&cid=t_148568_87_f&fid=36050&url=http%3A%2F%2Fblisstree.com%2Flive%2F193141%2F Did you take your vitamins? Brush your teeth? Read our newsletter? Oh, you didn’t read our Weekly Bliss newsletter? That’s probably because you haven’t signed up for it yet. Sign up now, or else you might miss the next edition. And then you will be so behind the times. Post from: BlissTree (Source: Breastfeeding 1-2-3) Breastfeeding 1-2-3 blogs http://www.medworm.com/rss/comments.php?id=3827042 Thu, 05 Aug 2010 20:00:40 +0100 3827042 http://www.medworm.com/index.php?rid=3805808&cid=t_148568_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2Fb-R9QIBkkxQ%2F By Daniel J. MitchellWriting in the Wall Street Journal, Peter Ferrara of the Institute for Policy Innovation explains that Washington budget deals don’t work because politicians never follow through on promised spending cuts. This is a very relevant argument, since President Obama’s so-called Deficit Reduction Commission supposedly is considering a deal featuring $3 of spending cuts for every $1 of tax increases (disturbingly reminiscent of what was promised — but never delivered — as part of the infamous 1982 TEFRA budget scam). Washington’s traditional approach to balancing the budget is to negotiate an agreement on a package of benefit cuts and tax increases. President Obama’s deficit commission seems likely to recommend just this strategy in Decembe... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=3805808 Fri, 30 Jul 2010 19:56:06 +0100 3805808 http://www.medworm.com/index.php?rid=3790670&cid=t_148568_87_f&fid=36050&url=http%3A%2F%2Fblisstree.com%2Flive%2Fcoming-very-soon-our-weekly-bliss-newsletter%2F photo: Thinkstock You are special. You know it. We know it. Everyone knows it. So let’s stop pretending you’re not. You are. Go to a mirror and say the following out loud with us: “I am special. Blisstree told me so.” Which is why you deserve something special, something insider-y, something exclusive (but not in a snobby way), something you really like, something you can actually use. That something is Weekly Bliss, our brand-new weekly newsletter that’s chock-full of Blisstree’s best nuggets of each week, plus cool extras including giveaways, contests, and solid gold bars. (Not that last thing. Sorry – we got excited.) Exclusive content, photo galleries, funny stuff, cool stuff, things that will make your friends and co-workers jealous, things that will make you happy. Stic... Breastfeeding 1-2-3 blogs http://www.medworm.com/rss/comments.php?id=3790670 Mon, 26 Jul 2010 15:48:01 +0100 3790670 http://www.medworm.com/index.php?rid=3607817&cid=t_148568_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FTSbBPhHxMwU%2F Here’s a sensational accusation for you. Paul Bisaro, the ceo of Watson Pharmaceuticals, filed papers in federal court the other day accusing the Federal Trade Commission of abusing its power in attempting to stop pay-for-delay deals, which the agency argues are anti-competitive and, therefore, harm consumers (see background). Bisaro claims the FTC harassed his company and used confidential FDA info in an effort to force Watson to strike a deal with Apotex, another generic drugmaker, to sell a version of Cephalon’s Provigil, a sleep-disorder drug. The FTC is challenging a 2005 deal between Cephalon and several generic drugmakers that were paid $300 million by arguing the payments bought market exclusivity. His charge follows a subpoena sought last year by the FTC to compel Bis... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3607817 Thu, 27 May 2010 18:06:48 +0100 3607817 http://www.medworm.com/index.php?rid=2354099&cid=t_148568_150_f&fid=38374&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FePharmaSummit%2F%7E3%2FT8lYYi8vf7M%2Fpharma-deals-exploding-in-2009.html According to TheStreet.com, pharma deals in the first quarter of 2009 were worth nearly 50% more than all the industry deals announced in 2008, according to a new report. The report, from The Mergermarket Group of New York and London, says deals in the quarter carried a combined value of $166 billion -- more than 10 times that of deals announced in last year's first quarter and well over the $114 billion in deals announced in all of 2008. Roche bought the 44% of Genentech (DNA Quote) it didn't already own for $47 billion. Pfizer (PFE Quote) is buying Wyeth for $64 billion and Merck (MRK Quote) is buying Schering-Plough (SGP Quote) for $43 billion.The deals seem evidence that despite the downturn big pharma still boasts the big cash flow to make major moves. In the case of Merck, the reason... ePharma Summit blogs http://www.medworm.com/rss/comments.php?id=2354099 Tue, 21 Apr 2009 14:02:00 +0100 2354099 http://www.medworm.com/index.php?rid=1991037&cid=t_148568_93_f&fid=36200&url=http%3A%2F%2Fblog.jammedph.com%2Fhp-g50-104nr-laptop-canon-pixma-all-in-one-printer%2F As the Christmas days are coming, people are flocking to stores, choosing for perfect gifts for their loved ones. Of course, searching for the best and cheap deals are always part of Christmas shopping. That’s the reason why bazaars always click on Christmas seasons. Online bargains and shopping are also hot during these days. They say that online shopping is way convenient and cheaper than “offline” shopping. This should be expected because people tend to get more practical nowadays. One of the best deals that could be given to your loved one is the HP G50 104NR Laptop with a Canon 3-in-1 printer at Bestbuy.com. The deal consists of the following: - Intel® Pentium® Dual-Core mobile processor T3200, 2GB DDR2 memory, 120GB hard drive and high-speed wireless networking (... Jammed: Full into Capacity blogs http://www.medworm.com/rss/comments.php?id=1991037 Tue, 25 Nov 2008 14:30:20 +0100 1991037 http://www.medworm.com/index.php?rid=1169928&cid=t_148568_85_f&fid=36194&url=http%3A%2F%2Ftesstermulo.com%2F2008%2F01%2F22%2Fget-the-best-deals-online-with-save-buckets%2F Buying online nowadays has become a breeze because of the convenience brought by Paypal transactions.  Add to that the temptation to spend those earnings from blogging.  But, even if it had been “easier” to earn those, it would still be prudent to choose carefully which products to buy and where to buy them online.  Like in real-life shopping, there are also good deals that can be found online.  In this aspect, Save Buckets can help out a lot.  Save Buckets is a price comparison site which helps you find the best deals on products that you’re interested.  To use the site is just as easy as entering keywords on a search engine like Google.  You can further specify the query by indicating the price range of the product you’re looking for and sort it based on relevance.  Also,... Prudence and Madness blogs http://www.medworm.com/rss/comments.php?id=1169928 Tue, 22 Jan 2008 12:32:28 +0100 1169928 http://www.medworm.com/index.php?rid=1028324&cid=t_148568_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F11%2F14%2Fnews-of-the-day%2F Ambit grabs 50M in a Series D. Their Lead is AC-220 a ph1 selective Flt3 compound.  In WO/2007/109120?   aetiology and limited data in: WO/2005/048953 Rigel tacks on 3M for the Japanese rights to R-763. (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=1028324 Thu, 15 Nov 2007 03:38:19 +0100 1028324 http://www.medworm.com/index.php?rid=900986&cid=t_148568_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F09%2F25%2Farray-bag-o-cash-en-route%2F 40M up front: …Array will grant Celgene an option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets… Looks like unpartnerds include: KSP, P38, P38/tie2, Erbb1-2,  RAF, TLR’s, etc… (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=900986 Tue, 25 Sep 2007 12:11:35 +0100 900986 http://www.medworm.com/index.php?rid=728711&cid=t_148568_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F05%2F24%2Fmerck-to-acquire-small-companies%2F Merck is moving away from a long time approach of internal organic growth to one of strategic acquisitions of small companies. Merck & Co. keen on small acquisitions: executive - washingtonpost.com: It will be interesting to keep an eye on this and see how they mange this. THey are getting late into the game and many deals, I’m sure are already in progress s they’ll have their work cut out for them finding those “hidden gems”. So many folks have already done deals I think they are ver many of these hidden gems remaining. Technorati Tags: Merck, pharma M&A, pharmaceutical deals Copyright © 2007 QDIS Blog. This Feed is for personal non-commercial use only. If you are not reading this material in your news aggregator, the site you are looking at is guilty... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728711 Thu, 24 May 2007 23:24:59 +0100 728711 http://www.medworm.com/index.php?rid=728717&cid=t_148568_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F04%2F28%2Fastrazeneca-to-buy-medimmune-mergers-and-acquisitions-continue%2F This news is somewhat dated now but the M&A activity in the pharmaceutical industry continues. Now AsraZeneca is purchasing Medimmune for $15.6 billion. AstraZeneca to buy MedImmune for $15.6B - Yahoo! News The two main products of interest are the children’s respiratory drug Synagis and a refrigerated version of FluMist inhaled influenza vaccine. This follows the current trend of major pharma increasing interest in vaccines. Novartis purchased Chiron and both Sanofi-Aventis and GlaxoSmithKline have sizable vaccine businesses. MedImmune had until recently, actively resisted any such take-over moves. I’m not sure why they finally relented and went forward with AstraZeneca. Maybe they finally got the price they wanted. Technorati Tags: AstraZeneca, Medimmune, pharma M&A,... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728717 Sat, 28 Apr 2007 17:46:25 +0100 728717 http://www.medworm.com/index.php?rid=728724&cid=t_148568_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F03%2F28%2Fmore-on-sanofi-aventis-bristol-myers-squibb-potential-mergersanofi-board-split-over-54bn-deal-to-acquire-bristol-myers-business-industry-sectors-health-timesonline%2F Seems the Sanofi BMS merger talks haven’t been without some truth to them. Now the Times Online is reporting that there is a split on the Sanofi side over strategy Sanofi board split over $54bn deal to acquire Bristol-Myers-Business-Industry Sectors-Health-TimesOnline The Times has learnt that a disagreement over strategy has emerged between Jean-François Dehecq, the Sanofi chairman, who favours a transformational deal with BMS, and Gérard Le Fur, his younger chief executive, who has emphasised the need to focus on the group’s internal drug research and development programme. The article goes on to say that the former view of merger with transformation is more probable. I think that it might be the less attractive strategy in the long run. I’m not a big fan of mergers sin... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728724 Thu, 29 Mar 2007 01:09:38 +0100 728724 http://www.medworm.com/index.php?rid=728738&cid=t_148568_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F03%2F12%2Fanother-major-merger-schering-plough-to-acquire-organon-biosciences-for-144-billion%2F An another major merger, Schering-Plough is acquiring Organon Biosciences, the animal and human health business of Akzo Nobel for $14.4 Billion. PharmaLive: Schering-Plough to Acquire Organon BioSciences Schering think this will be a good addition to their pipeline and the deal is excepted to close before the end of this year. The Organon website is pretty vague on the number and kinds of products in its pipeline so it is hard to judge without further research. They say they have products at various stages including several in pate stage development. They have the plan to fill at least one new major product each year for the next few years. As you can see, it is pretty lacking of details. They do mention two products; asenapine for treatment of bipolar and schizophrenia and sugammadex used... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728738 Mon, 12 Mar 2007 19:36:03 +0100 728738